Contrasting C4 Therapeutics (NASDAQ:CCCC) & Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) and C4 Therapeutics (NASDAQ:CCCC – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and C4 Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vertex Pharmaceuticals $12.00 billion 11.29 $3.95 billion $15.54 34.38
C4 Therapeutics $35.95 million 9.24 -$104.99 million ($0.72) -3.51

Vertex Pharmaceuticals has higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Vertex Pharmaceuticals and C4 Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vertex Pharmaceuticals 0 2 25 1 2.96
C4 Therapeutics 1 1 5 0 2.57

Vertex Pharmaceuticals presently has a consensus target price of $596.44, indicating a potential upside of 11.65%. C4 Therapeutics has a consensus target price of $8.50, indicating a potential upside of 235.97%. Given C4 Therapeutics’ higher possible upside, analysts clearly believe C4 Therapeutics is more favorable than Vertex Pharmaceuticals.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 3.16, indicating that its share price is 216% more volatile than the S&P 500.

Insider and Institutional Ownership

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Vertex Pharmaceuticals and C4 Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vertex Pharmaceuticals 30.70% 21.98% 15.50%
C4 Therapeutics -282.22% -37.71% -26.42%

Summary

Vertex Pharmaceuticals beats C4 Therapeutics on 12 of the 15 factors compared between the two stocks.

About Vertex Pharmaceuticals

(Get Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

About C4 Therapeutics

(Get Free Report)

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. Founded in 2015, it develops medicines designed to selectively remove disease-causing proteins, with a focus on cancer. The company uses its TORPEDO platform to design targeted protein degraders. These molecules are intended to bind a target protein and recruit the cell’s natural protein-disposal machinery, leading to the protein’s breakdown. C4 Therapeutics’ research and development programs include oral small-molecule candidates for oncology.

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.